Open AccessRevolutionizing Alzheimer's disease and clinical trials through biomarkers
Author(s) -
Mattsson Niklas,
Carrillo Maria C.,
Dean Robert A.,
Devous Michael D.,
Nikolcheva Tania,
Pesini Pedro,
Salter Hugh,
Potter William Z.,
Sperling Reisa S.,
Bateman Randall J.,
Bain Lisa J.,
Liu Enchi
Publication year - 2015
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2015.09.001
Subject(s) - neurodegeneration , standardization , clinical trial , medicine , disease , neuroinflammation , drug development , positron emission tomography , drug trial , neuroscience , neuropsychology , neuroimaging , biomarker , bioinformatics , medical physics , pathology , psychology , drug , psychiatry , cognition , biology , computer science , biochemistry , operating system
The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood‐based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.